nodes	percent_of_prediction	percent_of_DWPC	metapath
L-DOPA—SLC7A8—mammary gland—lung cancer	0.0101	0.0922	CbGeAlD
L-DOPA—PSIP1—bronchus—lung cancer	0.00839	0.0768	CbGeAlD
L-DOPA—SLC7A5—mammary gland—lung cancer	0.00781	0.0715	CbGeAlD
L-DOPA—PSIP1—trachea—lung cancer	0.00753	0.0689	CbGeAlD
L-DOPA—PSIP1—bone marrow—lung cancer	0.00597	0.0547	CbGeAlD
L-DOPA—DDC—respiratory system—lung cancer	0.00581	0.0532	CbGeAlD
L-DOPA—Masoprocol—IGF1R—lung cancer	0.00574	0.659	CrCbGaD
L-DOPA—PSIP1—Podofilox—Teniposide—lung cancer	0.0057	0.37	CbGdCrCtD
L-DOPA—PSIP1—lung—lung cancer	0.00541	0.0495	CbGeAlD
L-DOPA—SLC7A5—respiratory system—lung cancer	0.00521	0.0476	CbGeAlD
L-DOPA—SLC7A5—epithelium—lung cancer	0.00435	0.0398	CbGeAlD
L-DOPA—SLC7A5—bronchus—lung cancer	0.00429	0.0392	CbGeAlD
L-DOPA—SLC7A5—trachea—lung cancer	0.00385	0.0352	CbGeAlD
L-DOPA—PSIP1—lymph node—lung cancer	0.0037	0.0339	CbGeAlD
L-DOPA—SLC7A5—cardiac atrium—lung cancer	0.00361	0.0331	CbGeAlD
L-DOPA—SLC15A1—epithelium—lung cancer	0.00361	0.033	CbGeAlD
L-DOPA—SLC7A8—lung—lung cancer	0.00357	0.0326	CbGeAlD
L-DOPA—PSIP1—Podofilox—Etoposide—lung cancer	0.00339	0.22	CbGdCrCtD
L-DOPA—PSIP1—Teniposide—Etoposide—lung cancer	0.00339	0.22	CbGdCrCtD
L-DOPA—SLC16A10—epithelium—lung cancer	0.00333	0.0305	CbGeAlD
L-DOPA—DDC—lung—lung cancer	0.00309	0.0282	CbGeAlD
L-DOPA—SLC7A5—bone marrow—lung cancer	0.00305	0.0279	CbGeAlD
L-DOPA—PSIP1—Vinblastine—Vinorelbine—lung cancer	0.00292	0.19	CbGdCrCtD
L-DOPA—SLC7A5—lung—lung cancer	0.00276	0.0253	CbGeAlD
L-DOPA—DRD2—respiratory system—lung cancer	0.00252	0.0231	CbGeAlD
L-DOPA—SLC7A8—lymph node—lung cancer	0.00244	0.0223	CbGeAlD
L-DOPA—SLC16A10—lung—lung cancer	0.00212	0.0194	CbGeAlD
L-DOPA—DDC—lymph node—lung cancer	0.00211	0.0193	CbGeAlD
L-DOPA—SLC7A5—lymph node—lung cancer	0.00189	0.0173	CbGeAlD
L-DOPA—SLC16A10—lymph node—lung cancer	0.00145	0.0132	CbGeAlD
L-DOPA—DRD2—lung—lung cancer	0.00134	0.0123	CbGeAlD
L-DOPA—Aminosalicylic Acid—PTGS2—lung cancer	0.000777	0.0892	CrCbGaD
L-DOPA—Isoprenaline—CYP1A1—lung cancer	0.000669	0.0768	CrCbGaD
L-DOPA—Mesalazine—PTGS2—lung cancer	0.00061	0.07	CrCbGaD
L-DOPA—Liothyronine—ALB—lung cancer	0.000468	0.0537	CrCbGaD
L-DOPA—Liothyronine—ABCB1—lung cancer	0.000446	0.0512	CrCbGaD
L-DOPA—Feeling abnormal—Gemcitabine—lung cancer	0.000343	0.000659	CcSEcCtD
L-DOPA—Shock—Paclitaxel—lung cancer	0.000343	0.000658	CcSEcCtD
L-DOPA—Dizziness—Vinorelbine—lung cancer	0.000342	0.000658	CcSEcCtD
L-DOPA—Orthostatic hypotension—Doxorubicin—lung cancer	0.000342	0.000658	CcSEcCtD
L-DOPA—Thrombocytopenia—Paclitaxel—lung cancer	0.000341	0.000655	CcSEcCtD
L-DOPA—Anorexia—Etoposide—lung cancer	0.000338	0.000651	CcSEcCtD
L-DOPA—Abdominal pain—Irinotecan—lung cancer	0.000337	0.000649	CcSEcCtD
L-DOPA—Decreased appetite—Cisplatin—lung cancer	0.000337	0.000648	CcSEcCtD
L-DOPA—Hyperhidrosis—Paclitaxel—lung cancer	0.000337	0.000647	CcSEcCtD
L-DOPA—Nasopharyngitis—Doxorubicin—lung cancer	0.000335	0.000644	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Cisplatin—lung cancer	0.000335	0.000643	CcSEcCtD
L-DOPA—Anaemia—Docetaxel—lung cancer	0.000334	0.000642	CcSEcCtD
L-DOPA—Depression—Methotrexate—lung cancer	0.000332	0.000639	CcSEcCtD
L-DOPA—Anorexia—Paclitaxel—lung cancer	0.000332	0.000638	CcSEcCtD
L-DOPA—Hypotension—Etoposide—lung cancer	0.000332	0.000638	CcSEcCtD
L-DOPA—Gastritis—Doxorubicin—lung cancer	0.000332	0.000637	CcSEcCtD
L-DOPA—Pain—Cisplatin—lung cancer	0.000331	0.000637	CcSEcCtD
L-DOPA—Vomiting—Vinorelbine—lung cancer	0.000329	0.000633	CcSEcCtD
L-DOPA—Rash—Vinorelbine—lung cancer	0.000326	0.000627	CcSEcCtD
L-DOPA—Dermatitis—Vinorelbine—lung cancer	0.000326	0.000627	CcSEcCtD
L-DOPA—Hypotension—Paclitaxel—lung cancer	0.000325	0.000625	CcSEcCtD
L-DOPA—Headache—Vinorelbine—lung cancer	0.000324	0.000623	CcSEcCtD
L-DOPA—Syncope—Docetaxel—lung cancer	0.000324	0.000623	CcSEcCtD
L-DOPA—Dysphagia—Doxorubicin—lung cancer	0.000324	0.000623	CcSEcCtD
L-DOPA—Leukopenia—Docetaxel—lung cancer	0.000324	0.000622	CcSEcCtD
L-DOPA—Palpitations—Docetaxel—lung cancer	0.00032	0.000614	CcSEcCtD
L-DOPA—Feeling abnormal—Cisplatin—lung cancer	0.000319	0.000614	CcSEcCtD
L-DOPA—Paraesthesia—Etoposide—lung cancer	0.000319	0.000613	CcSEcCtD
L-DOPA—Loss of consciousness—Docetaxel—lung cancer	0.000318	0.000611	CcSEcCtD
L-DOPA—Dyspnoea—Etoposide—lung cancer	0.000317	0.000609	CcSEcCtD
L-DOPA—Somnolence—Etoposide—lung cancer	0.000316	0.000607	CcSEcCtD
L-DOPA—Cough—Docetaxel—lung cancer	0.000315	0.000607	CcSEcCtD
L-DOPA—Angina pectoris—Doxorubicin—lung cancer	0.000315	0.000606	CcSEcCtD
L-DOPA—Insomnia—Paclitaxel—lung cancer	0.000315	0.000605	CcSEcCtD
L-DOPA—Hypersensitivity—Irinotecan—lung cancer	0.000314	0.000605	CcSEcCtD
L-DOPA—Convulsion—Docetaxel—lung cancer	0.000313	0.000602	CcSEcCtD
L-DOPA—Paraesthesia—Paclitaxel—lung cancer	0.000313	0.000601	CcSEcCtD
L-DOPA—Hypertension—Docetaxel—lung cancer	0.000312	0.0006	CcSEcCtD
L-DOPA—Agranulocytosis—Methotrexate—lung cancer	0.000311	0.000598	CcSEcCtD
L-DOPA—Dyspnoea—Paclitaxel—lung cancer	0.00031	0.000597	CcSEcCtD
L-DOPA—Somnolence—Paclitaxel—lung cancer	0.000309	0.000595	CcSEcCtD
L-DOPA—Decreased appetite—Etoposide—lung cancer	0.000309	0.000593	CcSEcCtD
L-DOPA—Chest pain—Docetaxel—lung cancer	0.000308	0.000592	CcSEcCtD
L-DOPA—Nausea—Vinorelbine—lung cancer	0.000307	0.000591	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Etoposide—lung cancer	0.000307	0.000589	CcSEcCtD
L-DOPA—Dyspepsia—Paclitaxel—lung cancer	0.000306	0.000589	CcSEcCtD
L-DOPA—Asthenia—Irinotecan—lung cancer	0.000306	0.000589	CcSEcCtD
L-DOPA—Fatigue—Etoposide—lung cancer	0.000306	0.000588	CcSEcCtD
L-DOPA—Constipation—Etoposide—lung cancer	0.000304	0.000584	CcSEcCtD
L-DOPA—Pain—Etoposide—lung cancer	0.000304	0.000584	CcSEcCtD
L-DOPA—Decreased appetite—Paclitaxel—lung cancer	0.000303	0.000582	CcSEcCtD
L-DOPA—Dry mouth—Docetaxel—lung cancer	0.000301	0.000579	CcSEcCtD
L-DOPA—Upper respiratory tract infection—Doxorubicin—lung cancer	0.000301	0.000579	CcSEcCtD
L-DOPA—Haemoglobin—Methotrexate—lung cancer	0.000301	0.000578	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Paclitaxel—lung cancer	0.000301	0.000578	CcSEcCtD
L-DOPA—Fatigue—Paclitaxel—lung cancer	0.0003	0.000577	CcSEcCtD
L-DOPA—Haemorrhage—Methotrexate—lung cancer	0.000299	0.000575	CcSEcCtD
L-DOPA—Pollakiuria—Doxorubicin—lung cancer	0.000299	0.000575	CcSEcCtD
L-DOPA—Asthenia—Gemcitabine—lung cancer	0.000298	0.000574	CcSEcCtD
L-DOPA—Pain—Paclitaxel—lung cancer	0.000298	0.000572	CcSEcCtD
L-DOPA—Constipation—Paclitaxel—lung cancer	0.000298	0.000572	CcSEcCtD
L-DOPA—Confusional state—Docetaxel—lung cancer	0.000298	0.000572	CcSEcCtD
L-DOPA—Urinary tract disorder—Methotrexate—lung cancer	0.000296	0.000568	CcSEcCtD
L-DOPA—Oedema—Docetaxel—lung cancer	0.000295	0.000567	CcSEcCtD
L-DOPA—Weight increased—Doxorubicin—lung cancer	0.000295	0.000567	CcSEcCtD
L-DOPA—Pruritus—Gemcitabine—lung cancer	0.000294	0.000566	CcSEcCtD
L-DOPA—Urethral disorder—Methotrexate—lung cancer	0.000293	0.000564	CcSEcCtD
L-DOPA—Weight decreased—Doxorubicin—lung cancer	0.000293	0.000563	CcSEcCtD
L-DOPA—Feeling abnormal—Etoposide—lung cancer	0.000293	0.000562	CcSEcCtD
L-DOPA—Diarrhoea—Irinotecan—lung cancer	0.000292	0.000561	CcSEcCtD
L-DOPA—Gastrointestinal pain—Etoposide—lung cancer	0.00029	0.000558	CcSEcCtD
L-DOPA—Shock—Docetaxel—lung cancer	0.00029	0.000558	CcSEcCtD
L-DOPA—Thrombocytopenia—Docetaxel—lung cancer	0.000289	0.000555	CcSEcCtD
L-DOPA—Feeling abnormal—Paclitaxel—lung cancer	0.000287	0.000552	CcSEcCtD
L-DOPA—Hypersensitivity—Cisplatin—lung cancer	0.000286	0.000549	CcSEcCtD
L-DOPA—Gastrointestinal pain—Paclitaxel—lung cancer	0.000285	0.000547	CcSEcCtD
L-DOPA—Diarrhoea—Gemcitabine—lung cancer	0.000284	0.000547	CcSEcCtD
L-DOPA—Neuropathy peripheral—Doxorubicin—lung cancer	0.000283	0.000544	CcSEcCtD
L-DOPA—Dizziness—Irinotecan—lung cancer	0.000282	0.000543	CcSEcCtD
L-DOPA—Urticaria—Etoposide—lung cancer	0.000282	0.000542	CcSEcCtD
L-DOPA—Anorexia—Docetaxel—lung cancer	0.000281	0.000541	CcSEcCtD
L-DOPA—Abdominal pain—Etoposide—lung cancer	0.000281	0.00054	CcSEcCtD
L-DOPA—Urinary tract infection—Doxorubicin—lung cancer	0.000281	0.00054	CcSEcCtD
L-DOPA—Asthenia—Cisplatin—lung cancer	0.000278	0.000535	CcSEcCtD
L-DOPA—Urticaria—Paclitaxel—lung cancer	0.000277	0.000532	CcSEcCtD
L-DOPA—Hypotension—Docetaxel—lung cancer	0.000276	0.00053	CcSEcCtD
L-DOPA—Abdominal pain—Paclitaxel—lung cancer	0.000275	0.000529	CcSEcCtD
L-DOPA—Vomiting—Irinotecan—lung cancer	0.000271	0.000522	CcSEcCtD
L-DOPA—Agranulocytosis—Doxorubicin—lung cancer	0.000269	0.000518	CcSEcCtD
L-DOPA—Rash—Irinotecan—lung cancer	0.000269	0.000517	CcSEcCtD
L-DOPA—Dermatitis—Irinotecan—lung cancer	0.000269	0.000517	CcSEcCtD
L-DOPA—Headache—Irinotecan—lung cancer	0.000267	0.000514	CcSEcCtD
L-DOPA—Insomnia—Docetaxel—lung cancer	0.000267	0.000513	CcSEcCtD
L-DOPA—Diarrhoea—Cisplatin—lung cancer	0.000265	0.00051	CcSEcCtD
L-DOPA—Paraesthesia—Docetaxel—lung cancer	0.000265	0.000509	CcSEcCtD
L-DOPA—Alopecia—Methotrexate—lung cancer	0.000265	0.000509	CcSEcCtD
L-DOPA—Vomiting—Gemcitabine—lung cancer	0.000264	0.000508	CcSEcCtD
L-DOPA—Dyspnoea—Docetaxel—lung cancer	0.000263	0.000506	CcSEcCtD
L-DOPA—Somnolence—Docetaxel—lung cancer	0.000262	0.000504	CcSEcCtD
L-DOPA—Mental disorder—Methotrexate—lung cancer	0.000262	0.000504	CcSEcCtD
L-DOPA—Rash—Gemcitabine—lung cancer	0.000262	0.000504	CcSEcCtD
L-DOPA—Dermatitis—Gemcitabine—lung cancer	0.000262	0.000504	CcSEcCtD
L-DOPA—Hypersensitivity—Etoposide—lung cancer	0.000262	0.000503	CcSEcCtD
L-DOPA—Haemoglobin—Doxorubicin—lung cancer	0.000261	0.000501	CcSEcCtD
L-DOPA—Headache—Gemcitabine—lung cancer	0.00026	0.000501	CcSEcCtD
L-DOPA—Rhinitis—Doxorubicin—lung cancer	0.00026	0.0005	CcSEcCtD
L-DOPA—Dyspepsia—Docetaxel—lung cancer	0.00026	0.000499	CcSEcCtD
L-DOPA—Haemorrhage—Doxorubicin—lung cancer	0.000259	0.000498	CcSEcCtD
L-DOPA—Hypoaesthesia—Doxorubicin—lung cancer	0.000258	0.000496	CcSEcCtD
L-DOPA—Decreased appetite—Docetaxel—lung cancer	0.000257	0.000493	CcSEcCtD
L-DOPA—Hypersensitivity—Paclitaxel—lung cancer	0.000256	0.000493	CcSEcCtD
L-DOPA—Urinary tract disorder—Doxorubicin—lung cancer	0.000256	0.000492	CcSEcCtD
L-DOPA—Dysgeusia—Methotrexate—lung cancer	0.000255	0.000491	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Docetaxel—lung cancer	0.000255	0.00049	CcSEcCtD
L-DOPA—Asthenia—Etoposide—lung cancer	0.000255	0.00049	CcSEcCtD
L-DOPA—Fatigue—Docetaxel—lung cancer	0.000254	0.000489	CcSEcCtD
L-DOPA—Urethral disorder—Doxorubicin—lung cancer	0.000254	0.000488	CcSEcCtD
L-DOPA—Nausea—Irinotecan—lung cancer	0.000254	0.000487	CcSEcCtD
L-DOPA—Constipation—Docetaxel—lung cancer	0.000252	0.000485	CcSEcCtD
L-DOPA—Pain—Docetaxel—lung cancer	0.000252	0.000485	CcSEcCtD
L-DOPA—Back pain—Methotrexate—lung cancer	0.000252	0.000485	CcSEcCtD
L-DOPA—Pruritus—Etoposide—lung cancer	0.000251	0.000483	CcSEcCtD
L-DOPA—Asthenia—Paclitaxel—lung cancer	0.00025	0.00048	CcSEcCtD
L-DOPA—Nausea—Gemcitabine—lung cancer	0.000247	0.000475	CcSEcCtD
L-DOPA—Vomiting—Cisplatin—lung cancer	0.000246	0.000474	CcSEcCtD
L-DOPA—Pruritus—Paclitaxel—lung cancer	0.000246	0.000474	CcSEcCtD
L-DOPA—Vision blurred—Methotrexate—lung cancer	0.000246	0.000472	CcSEcCtD
L-DOPA—Rash—Cisplatin—lung cancer	0.000244	0.00047	CcSEcCtD
L-DOPA—Dermatitis—Cisplatin—lung cancer	0.000244	0.000469	CcSEcCtD
L-DOPA—Feeling abnormal—Docetaxel—lung cancer	0.000243	0.000467	CcSEcCtD
L-DOPA—Diarrhoea—Etoposide—lung cancer	0.000243	0.000467	CcSEcCtD
L-DOPA—Ill-defined disorder—Methotrexate—lung cancer	0.000242	0.000465	CcSEcCtD
L-DOPA—Gastrointestinal pain—Docetaxel—lung cancer	0.000241	0.000464	CcSEcCtD
L-DOPA—Anaemia—Methotrexate—lung cancer	0.000241	0.000463	CcSEcCtD
L-DOPA—Flushing—Doxorubicin—lung cancer	0.000241	0.000462	CcSEcCtD
L-DOPA—Diarrhoea—Paclitaxel—lung cancer	0.000238	0.000458	CcSEcCtD
L-DOPA—Malaise—Methotrexate—lung cancer	0.000235	0.000452	CcSEcCtD
L-DOPA—Dizziness—Etoposide—lung cancer	0.000235	0.000451	CcSEcCtD
L-DOPA—Abdominal pain—Docetaxel—lung cancer	0.000233	0.000448	CcSEcCtD
L-DOPA—Leukopenia—Methotrexate—lung cancer	0.000233	0.000448	CcSEcCtD
L-DOPA—Arrhythmia—Doxorubicin—lung cancer	0.000232	0.000445	CcSEcCtD
L-DOPA—Dizziness—Paclitaxel—lung cancer	0.00023	0.000443	CcSEcCtD
L-DOPA—Nausea—Cisplatin—lung cancer	0.00023	0.000443	CcSEcCtD
L-DOPA—Alopecia—Doxorubicin—lung cancer	0.000229	0.00044	CcSEcCtD
L-DOPA—Cough—Methotrexate—lung cancer	0.000227	0.000437	CcSEcCtD
L-DOPA—Mental disorder—Doxorubicin—lung cancer	0.000227	0.000437	CcSEcCtD
L-DOPA—Convulsion—Methotrexate—lung cancer	0.000226	0.000434	CcSEcCtD
L-DOPA—Vomiting—Etoposide—lung cancer	0.000226	0.000434	CcSEcCtD
L-DOPA—Rash—Etoposide—lung cancer	0.000224	0.00043	CcSEcCtD
L-DOPA—Dermatitis—Etoposide—lung cancer	0.000224	0.00043	CcSEcCtD
L-DOPA—Headache—Etoposide—lung cancer	0.000222	0.000428	CcSEcCtD
L-DOPA—Flatulence—Doxorubicin—lung cancer	0.000222	0.000427	CcSEcCtD
L-DOPA—Chest pain—Methotrexate—lung cancer	0.000222	0.000427	CcSEcCtD
L-DOPA—Tension—Doxorubicin—lung cancer	0.000221	0.000426	CcSEcCtD
L-DOPA—Vomiting—Paclitaxel—lung cancer	0.000221	0.000426	CcSEcCtD
L-DOPA—Dysgeusia—Doxorubicin—lung cancer	0.000221	0.000425	CcSEcCtD
L-DOPA—Rash—Paclitaxel—lung cancer	0.000219	0.000422	CcSEcCtD
L-DOPA—Dermatitis—Paclitaxel—lung cancer	0.000219	0.000422	CcSEcCtD
L-DOPA—Discomfort—Methotrexate—lung cancer	0.000219	0.000421	CcSEcCtD
L-DOPA—Nervousness—Doxorubicin—lung cancer	0.000219	0.000421	CcSEcCtD
L-DOPA—Back pain—Doxorubicin—lung cancer	0.000218	0.00042	CcSEcCtD
L-DOPA—Headache—Paclitaxel—lung cancer	0.000218	0.000419	CcSEcCtD
L-DOPA—Hypersensitivity—Docetaxel—lung cancer	0.000217	0.000418	CcSEcCtD
L-DOPA—Muscle spasms—Doxorubicin—lung cancer	0.000217	0.000417	CcSEcCtD
L-DOPA—Confusional state—Methotrexate—lung cancer	0.000214	0.000412	CcSEcCtD
L-DOPA—Vision blurred—Doxorubicin—lung cancer	0.000213	0.000409	CcSEcCtD
L-DOPA—Asthenia—Docetaxel—lung cancer	0.000212	0.000407	CcSEcCtD
L-DOPA—Nausea—Etoposide—lung cancer	0.000211	0.000405	CcSEcCtD
L-DOPA—Ill-defined disorder—Doxorubicin—lung cancer	0.000209	0.000402	CcSEcCtD
L-DOPA—Pruritus—Docetaxel—lung cancer	0.000209	0.000401	CcSEcCtD
L-DOPA—Anaemia—Doxorubicin—lung cancer	0.000209	0.000401	CcSEcCtD
L-DOPA—Thrombocytopenia—Methotrexate—lung cancer	0.000208	0.0004	CcSEcCtD
L-DOPA—Agitation—Doxorubicin—lung cancer	0.000207	0.000399	CcSEcCtD
L-DOPA—Nausea—Paclitaxel—lung cancer	0.000207	0.000398	CcSEcCtD
L-DOPA—Hyperhidrosis—Methotrexate—lung cancer	0.000206	0.000395	CcSEcCtD
L-DOPA—Malaise—Doxorubicin—lung cancer	0.000203	0.000391	CcSEcCtD
L-DOPA—Anorexia—Methotrexate—lung cancer	0.000203	0.00039	CcSEcCtD
L-DOPA—Syncope—Doxorubicin—lung cancer	0.000202	0.000389	CcSEcCtD
L-DOPA—Leukopenia—Doxorubicin—lung cancer	0.000202	0.000388	CcSEcCtD
L-DOPA—Diarrhoea—Docetaxel—lung cancer	0.000202	0.000388	CcSEcCtD
L-DOPA—Palpitations—Doxorubicin—lung cancer	0.000199	0.000383	CcSEcCtD
L-DOPA—Hypotension—Methotrexate—lung cancer	0.000199	0.000382	CcSEcCtD
L-DOPA—Loss of consciousness—Doxorubicin—lung cancer	0.000198	0.000381	CcSEcCtD
L-DOPA—Cough—Doxorubicin—lung cancer	0.000197	0.000379	CcSEcCtD
L-DOPA—Convulsion—Doxorubicin—lung cancer	0.000196	0.000376	CcSEcCtD
L-DOPA—Dizziness—Docetaxel—lung cancer	0.000195	0.000375	CcSEcCtD
L-DOPA—Hypertension—Doxorubicin—lung cancer	0.000195	0.000375	CcSEcCtD
L-DOPA—Insomnia—Methotrexate—lung cancer	0.000192	0.00037	CcSEcCtD
L-DOPA—Chest pain—Doxorubicin—lung cancer	0.000192	0.000369	CcSEcCtD
L-DOPA—Anxiety—Doxorubicin—lung cancer	0.000191	0.000368	CcSEcCtD
L-DOPA—Paraesthesia—Methotrexate—lung cancer	0.000191	0.000367	CcSEcCtD
L-DOPA—Discomfort—Doxorubicin—lung cancer	0.00019	0.000365	CcSEcCtD
L-DOPA—Dyspnoea—Methotrexate—lung cancer	0.00019	0.000365	CcSEcCtD
L-DOPA—Somnolence—Methotrexate—lung cancer	0.000189	0.000363	CcSEcCtD
L-DOPA—Dry mouth—Doxorubicin—lung cancer	0.000188	0.000361	CcSEcCtD
L-DOPA—Vomiting—Docetaxel—lung cancer	0.000188	0.000361	CcSEcCtD
L-DOPA—Dyspepsia—Methotrexate—lung cancer	0.000187	0.00036	CcSEcCtD
L-DOPA—Rash—Docetaxel—lung cancer	0.000186	0.000358	CcSEcCtD
L-DOPA—Dermatitis—Docetaxel—lung cancer	0.000186	0.000357	CcSEcCtD
L-DOPA—Confusional state—Doxorubicin—lung cancer	0.000186	0.000357	CcSEcCtD
L-DOPA—Decreased appetite—Methotrexate—lung cancer	0.000185	0.000355	CcSEcCtD
L-DOPA—Headache—Docetaxel—lung cancer	0.000185	0.000355	CcSEcCtD
L-DOPA—Oedema—Doxorubicin—lung cancer	0.000184	0.000354	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Methotrexate—lung cancer	0.000184	0.000353	CcSEcCtD
L-DOPA—Fatigue—Methotrexate—lung cancer	0.000183	0.000352	CcSEcCtD
L-DOPA—Pain—Methotrexate—lung cancer	0.000182	0.00035	CcSEcCtD
L-DOPA—Shock—Doxorubicin—lung cancer	0.000181	0.000348	CcSEcCtD
L-DOPA—Thrombocytopenia—Doxorubicin—lung cancer	0.00018	0.000347	CcSEcCtD
L-DOPA—Hyperhidrosis—Doxorubicin—lung cancer	0.000178	0.000342	CcSEcCtD
L-DOPA—Anorexia—Doxorubicin—lung cancer	0.000176	0.000337	CcSEcCtD
L-DOPA—Nausea—Docetaxel—lung cancer	0.000175	0.000337	CcSEcCtD
L-DOPA—Feeling abnormal—Methotrexate—lung cancer	0.000175	0.000337	CcSEcCtD
L-DOPA—Gastrointestinal pain—Methotrexate—lung cancer	0.000174	0.000334	CcSEcCtD
L-DOPA—Hypotension—Doxorubicin—lung cancer	0.000172	0.000331	CcSEcCtD
L-DOPA—Urticaria—Methotrexate—lung cancer	0.000169	0.000325	CcSEcCtD
L-DOPA—Abdominal pain—Methotrexate—lung cancer	0.000168	0.000323	CcSEcCtD
L-DOPA—Insomnia—Doxorubicin—lung cancer	0.000167	0.00032	CcSEcCtD
L-DOPA—Paraesthesia—Doxorubicin—lung cancer	0.000165	0.000318	CcSEcCtD
L-DOPA—Dyspnoea—Doxorubicin—lung cancer	0.000164	0.000316	CcSEcCtD
L-DOPA—Somnolence—Doxorubicin—lung cancer	0.000164	0.000315	CcSEcCtD
L-DOPA—Dyspepsia—Doxorubicin—lung cancer	0.000162	0.000312	CcSEcCtD
L-DOPA—Decreased appetite—Doxorubicin—lung cancer	0.00016	0.000308	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Doxorubicin—lung cancer	0.000159	0.000306	CcSEcCtD
L-DOPA—Fatigue—Doxorubicin—lung cancer	0.000159	0.000305	CcSEcCtD
L-DOPA—Constipation—Doxorubicin—lung cancer	0.000157	0.000303	CcSEcCtD
L-DOPA—Pain—Doxorubicin—lung cancer	0.000157	0.000303	CcSEcCtD
L-DOPA—Hypersensitivity—Methotrexate—lung cancer	0.000157	0.000301	CcSEcCtD
L-DOPA—Asthenia—Methotrexate—lung cancer	0.000153	0.000293	CcSEcCtD
L-DOPA—Feeling abnormal—Doxorubicin—lung cancer	0.000152	0.000292	CcSEcCtD
L-DOPA—Gastrointestinal pain—Doxorubicin—lung cancer	0.000151	0.000289	CcSEcCtD
L-DOPA—Pruritus—Methotrexate—lung cancer	0.00015	0.000289	CcSEcCtD
L-DOPA—Urticaria—Doxorubicin—lung cancer	0.000146	0.000281	CcSEcCtD
L-DOPA—Abdominal pain—Doxorubicin—lung cancer	0.000146	0.00028	CcSEcCtD
L-DOPA—Diarrhoea—Methotrexate—lung cancer	0.000146	0.00028	CcSEcCtD
L-DOPA—Dizziness—Methotrexate—lung cancer	0.000141	0.00027	CcSEcCtD
L-DOPA—Hypersensitivity—Doxorubicin—lung cancer	0.000136	0.000261	CcSEcCtD
L-DOPA—Vomiting—Methotrexate—lung cancer	0.000135	0.00026	CcSEcCtD
L-DOPA—Rash—Methotrexate—lung cancer	0.000134	0.000258	CcSEcCtD
L-DOPA—Dermatitis—Methotrexate—lung cancer	0.000134	0.000258	CcSEcCtD
L-DOPA—Headache—Methotrexate—lung cancer	0.000133	0.000256	CcSEcCtD
L-DOPA—Asthenia—Doxorubicin—lung cancer	0.000132	0.000254	CcSEcCtD
L-DOPA—Pruritus—Doxorubicin—lung cancer	0.00013	0.00025	CcSEcCtD
L-DOPA—Nausea—Methotrexate—lung cancer	0.000126	0.000243	CcSEcCtD
L-DOPA—Diarrhoea—Doxorubicin—lung cancer	0.000126	0.000242	CcSEcCtD
L-DOPA—Dizziness—Doxorubicin—lung cancer	0.000122	0.000234	CcSEcCtD
L-DOPA—Vomiting—Doxorubicin—lung cancer	0.000117	0.000225	CcSEcCtD
L-DOPA—Rash—Doxorubicin—lung cancer	0.000116	0.000223	CcSEcCtD
L-DOPA—Dermatitis—Doxorubicin—lung cancer	0.000116	0.000223	CcSEcCtD
L-DOPA—Headache—Doxorubicin—lung cancer	0.000115	0.000222	CcSEcCtD
L-DOPA—Nausea—Doxorubicin—lung cancer	0.000109	0.00021	CcSEcCtD
L-DOPA—DRD2—Signaling Pathways—AVP—lung cancer	2.22e-05	6.41e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—APOA1—lung cancer	2.22e-05	6.41e-05	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—PIK3CB—lung cancer	2.21e-05	6.39e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—KDR—lung cancer	2.2e-05	6.35e-05	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—AKT1—lung cancer	2.2e-05	6.35e-05	CbGpPWpGaD
L-DOPA—DDC—Metabolism—PIK3CA—lung cancer	2.2e-05	6.34e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—MAPK3—lung cancer	2.18e-05	6.31e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CASP3—lung cancer	2.18e-05	6.29e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—IL2—lung cancer	2.17e-05	6.28e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—POMC—lung cancer	2.17e-05	6.27e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—IL6—lung cancer	2.16e-05	6.25e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—BRAF—lung cancer	2.14e-05	6.19e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ENO1—lung cancer	2.14e-05	6.18e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IGF1R—lung cancer	2.14e-05	6.17e-05	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—CXCL8—lung cancer	2.13e-05	6.14e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CCND1—lung cancer	2.12e-05	6.12e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—IL6R—lung cancer	2.12e-05	6.11e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—JUN—lung cancer	2.12e-05	6.11e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CREBBP—lung cancer	2.11e-05	6.1e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—HES1—lung cancer	2.1e-05	6.06e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—EGFR—lung cancer	2.08e-05	6e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—RAF1—lung cancer	2.06e-05	5.95e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—MMP9—lung cancer	2.06e-05	5.94e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—KIT—lung cancer	2.05e-05	5.93e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—APC—lung cancer	2.05e-05	5.93e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PIK3CG—lung cancer	2.05e-05	5.93e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—NRAS—lung cancer	2.05e-05	5.93e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CDKN1A—lung cancer	2.05e-05	5.92e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—PTEN—lung cancer	2.05e-05	5.91e-05	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—IL2—lung cancer	2.03e-05	5.87e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—EGF—lung cancer	2.03e-05	5.86e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PIK3CG—lung cancer	2.03e-05	5.85e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—APC—lung cancer	2.03e-05	5.85e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—KIT—lung cancer	2.03e-05	5.85e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—NRAS—lung cancer	2.03e-05	5.85e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MAP2K1—lung cancer	2.02e-05	5.83e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—PIK3CB—lung cancer	2.01e-05	5.8e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PIK3CD—lung cancer	2.01e-05	5.79e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—EGF—lung cancer	2e-05	5.78e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—AKT1—lung cancer	2e-05	5.76e-05	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—PIK3CA—lung cancer	1.99e-05	5.73e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—MAPK3—lung cancer	1.97e-05	5.68e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—KRAS—lung cancer	1.96e-05	5.67e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—POMC—lung cancer	1.95e-05	5.64e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—EP300—lung cancer	1.95e-05	5.63e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—MAPK3—lung cancer	1.94e-05	5.6e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—CXCL8—lung cancer	1.93e-05	5.58e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—BRAF—lung cancer	1.93e-05	5.57e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—POMC—lung cancer	1.93e-05	5.57e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CYP2E1—lung cancer	1.92e-05	5.55e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—ERBB3—lung cancer	1.92e-05	5.54e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IL6R—lung cancer	1.91e-05	5.5e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—BRAF—lung cancer	1.9e-05	5.5e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CREBBP—lung cancer	1.9e-05	5.5e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—NQO1—lung cancer	1.9e-05	5.49e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—SRC—lung cancer	1.9e-05	5.48e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IL6R—lung cancer	1.88e-05	5.43e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CREBBP—lung cancer	1.88e-05	5.42e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—EGFR—lung cancer	1.87e-05	5.4e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—VEGFA—lung cancer	1.85e-05	5.33e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—IL2—lung cancer	1.85e-05	5.33e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—EGFR—lung cancer	1.85e-05	5.33e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TERT—lung cancer	1.84e-05	5.31e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—STAT3—lung cancer	1.83e-05	5.28e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—NRAS—lung cancer	1.83e-05	5.27e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MAP2K1—lung cancer	1.82e-05	5.24e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PIK3CD—lung cancer	1.81e-05	5.21e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—PIK3CA—lung cancer	1.8e-05	5.21e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MDM2—lung cancer	1.8e-05	5.19e-05	CbGpPWpGaD
L-DOPA—DDC—Metabolism—AKT1—lung cancer	1.79e-05	5.18e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MAP2K1—lung cancer	1.79e-05	5.18e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—RAF1—lung cancer	1.79e-05	5.17e-05	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—PIK3CA—lung cancer	1.79e-05	5.16e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—FGFR1—lung cancer	1.79e-05	5.16e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PIK3CD—lung cancer	1.78e-05	5.14e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—ERBB2—lung cancer	1.77e-05	5.11e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—KRAS—lung cancer	1.77e-05	5.1e-05	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—PIK3CA—lung cancer	1.76e-05	5.09e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—HIF1A—lung cancer	1.76e-05	5.08e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—MAPK3—lung cancer	1.75e-05	5.05e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MTOR—lung cancer	1.75e-05	5.04e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PIK3CB—lung cancer	1.75e-05	5.04e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—KRAS—lung cancer	1.74e-05	5.03e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—STK11—lung cancer	1.71e-05	4.94e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—MYC—lung cancer	1.7e-05	4.91e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—APOA1—lung cancer	1.7e-05	4.9e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—KDR—lung cancer	1.68e-05	4.86e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CXCL8—lung cancer	1.68e-05	4.85e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—HRAS—lung cancer	1.67e-05	4.82e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—EGFR—lung cancer	1.66e-05	4.8e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—PIK3CA—lung cancer	1.62e-05	4.69e-05	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—AKT1—lung cancer	1.62e-05	4.68e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MDM2—lung cancer	1.62e-05	4.67e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—RAF1—lung cancer	1.61e-05	4.65e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CASP3—lung cancer	1.61e-05	4.64e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—IL2—lung cancer	1.61e-05	4.63e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—PIK3CA—lung cancer	1.6e-05	4.62e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—IL6—lung cancer	1.6e-05	4.61e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MDM2—lung cancer	1.6e-05	4.61e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—ERBB2—lung cancer	1.59e-05	4.6e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—RAF1—lung cancer	1.59e-05	4.59e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GSTP1—lung cancer	1.58e-05	4.57e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PIK3CB—lung cancer	1.57e-05	4.54e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MTOR—lung cancer	1.57e-05	4.54e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—ERBB2—lung cancer	1.57e-05	4.54e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—KRAS—lung cancer	1.57e-05	4.54e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CCND1—lung cancer	1.56e-05	4.52e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—JUN—lung cancer	1.56e-05	4.51e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PIK3CB—lung cancer	1.55e-05	4.48e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MTOR—lung cancer	1.55e-05	4.48e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—KIT—lung cancer	1.55e-05	4.47e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—APC—lung cancer	1.55e-05	4.47e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PIK3CG—lung cancer	1.55e-05	4.47e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—NRAS—lung cancer	1.55e-05	4.47e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CAT—lung cancer	1.54e-05	4.45e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—EGF—lung cancer	1.53e-05	4.42e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MMP9—lung cancer	1.52e-05	4.38e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CDKN1A—lung cancer	1.51e-05	4.37e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CXCL8—lung cancer	1.51e-05	4.36e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PTEN—lung cancer	1.51e-05	4.36e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—HRAS—lung cancer	1.5e-05	4.34e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ABCB1—lung cancer	1.5e-05	4.33e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CXCL8—lung cancer	1.49e-05	4.31e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—MAPK3—lung cancer	1.48e-05	4.29e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—HRAS—lung cancer	1.48e-05	4.28e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—POMC—lung cancer	1.48e-05	4.26e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—TYMS—lung cancer	1.47e-05	4.25e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—AKT1—lung cancer	1.47e-05	4.25e-05	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—AKT1—lung cancer	1.46e-05	4.22e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—BRAF—lung cancer	1.46e-05	4.21e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GSTM1—lung cancer	1.46e-05	4.2e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CASP3—lung cancer	1.45e-05	4.18e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IL2—lung cancer	1.44e-05	4.17e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—PIK3CA—lung cancer	1.44e-05	4.17e-05	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—AKT1—lung cancer	1.44e-05	4.16e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—EP300—lung cancer	1.44e-05	4.16e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IL6R—lung cancer	1.44e-05	4.16e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—IL6—lung cancer	1.44e-05	4.15e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CREBBP—lung cancer	1.44e-05	4.15e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CASP3—lung cancer	1.43e-05	4.12e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IL2—lung cancer	1.43e-05	4.12e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—IL6—lung cancer	1.42e-05	4.09e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—EGFR—lung cancer	1.41e-05	4.08e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CCND1—lung cancer	1.41e-05	4.07e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—JUN—lung cancer	1.41e-05	4.06e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—SRC—lung cancer	1.4e-05	4.04e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—TP53—lung cancer	1.4e-05	4.03e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CCND1—lung cancer	1.39e-05	4.01e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—JUN—lung cancer	1.39e-05	4e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CYP1A1—lung cancer	1.38e-05	3.99e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MAP2K1—lung cancer	1.37e-05	3.96e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ERCC2—lung cancer	1.37e-05	3.95e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MMP9—lung cancer	1.37e-05	3.95e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—VEGFA—lung cancer	1.36e-05	3.94e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PIK3CD—lung cancer	1.36e-05	3.93e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CDKN1A—lung cancer	1.36e-05	3.93e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PTEN—lung cancer	1.36e-05	3.92e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—STAT3—lung cancer	1.35e-05	3.9e-05	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—PIK3CA—lung cancer	1.35e-05	3.9e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MMP9—lung cancer	1.35e-05	3.89e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—NRAS—lung cancer	1.35e-05	3.89e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CDKN1A—lung cancer	1.34e-05	3.88e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PTEN—lung cancer	1.34e-05	3.87e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—HRAS—lung cancer	1.34e-05	3.86e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—KRAS—lung cancer	1.33e-05	3.85e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—AKT1—lung cancer	1.33e-05	3.83e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—AKT1—lung cancer	1.31e-05	3.78e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—EP300—lung cancer	1.3e-05	3.74e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MAPK3—lung cancer	1.29e-05	3.72e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—EP300—lung cancer	1.28e-05	3.69e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—IL6—lung cancer	1.28e-05	3.69e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—SRC—lung cancer	1.26e-05	3.64e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MYC—lung cancer	1.26e-05	3.62e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—SRC—lung cancer	1.24e-05	3.59e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—VEGFA—lung cancer	1.23e-05	3.54e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—EGFR—lung cancer	1.23e-05	3.54e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—PIK3CA—lung cancer	1.23e-05	3.54e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MDM2—lung cancer	1.22e-05	3.52e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—RAF1—lung cancer	1.22e-05	3.51e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—STAT3—lung cancer	1.22e-05	3.51e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—NRAS—lung cancer	1.21e-05	3.5e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—VEGFA—lung cancer	1.21e-05	3.5e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—ERBB2—lung cancer	1.2e-05	3.47e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—STAT3—lung cancer	1.2e-05	3.46e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—NRAS—lung cancer	1.2e-05	3.45e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PIK3CB—lung cancer	1.19e-05	3.43e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MTOR—lung cancer	1.19e-05	3.43e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—APOA1—lung cancer	1.18e-05	3.42e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—AKT1—lung cancer	1.18e-05	3.4e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MAPK3—lung cancer	1.16e-05	3.35e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—KRAS—lung cancer	1.16e-05	3.35e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MAPK3—lung cancer	1.15e-05	3.31e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CXCL8—lung cancer	1.14e-05	3.3e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—HRAS—lung cancer	1.13e-05	3.27e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MYC—lung cancer	1.13e-05	3.26e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MYC—lung cancer	1.11e-05	3.22e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—EGFR—lung cancer	1.11e-05	3.19e-05	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—AKT1—lung cancer	1.1e-05	3.18e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CASP3—lung cancer	1.09e-05	3.15e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IL2—lung cancer	1.09e-05	3.15e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—EGFR—lung cancer	1.09e-05	3.15e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—IL6—lung cancer	1.09e-05	3.13e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PIK3CG—lung cancer	1.08e-05	3.12e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PIK3CA—lung cancer	1.07e-05	3.08e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CCND1—lung cancer	1.06e-05	3.07e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—JUN—lung cancer	1.06e-05	3.06e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—KRAS—lung cancer	1.04e-05	3.01e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MMP9—lung cancer	1.03e-05	2.98e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—TP53—lung cancer	1.03e-05	2.98e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—KRAS—lung cancer	1.03e-05	2.97e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—POMC—lung cancer	1.03e-05	2.97e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CDKN1A—lung cancer	1.03e-05	2.97e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PTEN—lung cancer	1.03e-05	2.96e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CREBBP—lung cancer	1e-05	2.89e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—AKT1—lung cancer	1e-05	2.89e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—HRAS—lung cancer	9.86e-06	2.85e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—EP300—lung cancer	9.79e-06	2.83e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PIK3CA—lung cancer	9.59e-06	2.77e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—SRC—lung cancer	9.52e-06	2.75e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PIK3CD—lung cancer	9.51e-06	2.74e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PIK3CA—lung cancer	9.46e-06	2.73e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—IL6—lung cancer	9.43e-06	2.72e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ALB—lung cancer	9.39e-06	2.71e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—TP53—lung cancer	9.28e-06	2.68e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—VEGFA—lung cancer	9.27e-06	2.68e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—STAT3—lung cancer	9.18e-06	2.65e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—NRAS—lung cancer	9.16e-06	2.64e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—TP53—lung cancer	9.16e-06	2.64e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—HRAS—lung cancer	8.87e-06	2.56e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MAPK3—lung cancer	8.77e-06	2.53e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—HRAS—lung cancer	8.76e-06	2.53e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—AKT1—lung cancer	8.7e-06	2.51e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MYC—lung cancer	8.53e-06	2.46e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IL6—lung cancer	8.49e-06	2.45e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IL6—lung cancer	8.38e-06	2.42e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—EGFR—lung cancer	8.34e-06	2.41e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PIK3CB—lung cancer	8.29e-06	2.39e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PTGS2—lung cancer	8.21e-06	2.37e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—KRAS—lung cancer	7.88e-06	2.28e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—AKT1—lung cancer	7.84e-06	2.26e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—AKT1—lung cancer	7.73e-06	2.23e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PIK3CA—lung cancer	7.24e-06	2.09e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PTEN—lung cancer	7.16e-06	2.07e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TP53—lung cancer	7.01e-06	2.02e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—EP300—lung cancer	6.83e-06	1.97e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—HRAS—lung cancer	6.7e-06	1.93e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IL6—lung cancer	6.41e-06	1.85e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—AKT1—lung cancer	5.92e-06	1.71e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PIK3CA—lung cancer	5.05e-06	1.46e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—AKT1—lung cancer	4.13e-06	1.19e-05	CbGpPWpGaD
